Global Protein Therapeutics Market – Industry Trends and Forecast to 2030

Protein Therapeutics Market Analysis and Size

The global protein therapy market is growing steadily due to increasing demand for targeted and personalized therapies. Advances in biotechnology and the rise of chronic diseases are fuelling market expansion with a focus on monoclonal antibodies and recombinant proteins.  Developing economies and increasing research and development investments are driving the market and creating opportunities for innovation and market expansion.

Data Bridge Market Research analyses that the protein global therapeutics market which was USD 115.17 billion in 2022, is expected to reach USD 290.74 billion by 2030, and is expected to undergo a CAGR of 6.68% during the forecast period 2023-2030. This indicates that the market value. “Monoclonal Antibodies” dominates the product segment of the protein global therapeutics market owing to the growing demand for monoclonal antibodies for protein therapeutics. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Protein Therapeutics Market Scope and Segmentation

Market Definition

Protein therapeutics supply the body with proteins in specific quantities (as needed by the patient) for the treatment of various medical conditions, such as diabetes, anaemia, chronic renal failure or structural reconstruction. Therapeutic proteins are fast-acting and potent drugs and have proven to be very effective in treating a wide variety of diseases. With a growing understanding of the molecular mechanisms of illness, opportunities to improve protein therapeutics will continue to exist.            

Global Protein Therapeutics Market Dynamics

Drivers

• Increasing Prevalence of Chronic Diseases

Globally increasing burden of chronic diseases such as cancer, diabetes, cardiovascular diseases and autoimmune diseases is a major driver of the global protein therapy market. Protein-based therapies offer targeted therapeutic options with high specificity and efficacy, making them valuable in the management and treatment of these complex diseases.

• Technological Advancements in Protein Engineering

Advances in protein engineering, including recombinant DNA technology, monoclonal antibody production, and protein expression systems, have revolutionized the development of protein therapeutics. These technological advancements have enabled the production of highly specific and potent protein drugs, with improved pharmacokinetics and reduced immunogenicity.

• Increasing Demand for Personalized Medicine

The demand for personalized medicine is increasing, which requires tailoring treatment based on a person's genetic profile, disease characteristics and response to treatment. Protein drugs, such as monoclonal antibodies and bispecific antibodies, can be tailored to target specific molecular targets, enabling individualized and precise therapies.

• Growing Investment for Healthcare Facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Rising Demand for Targeted Therapies

There is a demand for targeted therapies that offer high specificity and efficacy in the treatment of various diseases. Protein therapies, such as monoclonal antibodies and fusion proteins, offer targeted approaches by binding specifically to disease-related targets, leading to improved treatment outcomes. This gives the market an opportunity to develop and commercialize new protein-based drugs that target specific diseases.

• Expansion in Emerging Markets

Emerging markets such as China, India, Brazil and other countries in Asia and Latin America are seeing significant increases in healthcare spending and access to advanced treatments. The expansion creates a favorable market environment for protein therapy, as these areas offer untapped potential and large patient populations. Protein drugs can be adapted and tailored to the specific needs of these markets, thus increasing market reach and revenue.

Restraints/ Challenges

• High Development and Manufacturing Costs

Development and manufacturing of protein drugs involves complex processes, extensive research and strict quality control measures. This results in high expenditure on research and development, manufacturing and regulatory compliance. High costs significantly limit the market and limit the availability and affordability of protein-based therapies, especially in resource-constrained healthcare systems.

• Stringent Regulatory Requirements

Protein therapeutic preparations are subject to strict requirements for safety, efficacy and quality. Regulatory agencies set strict guidelines and standards for their development, testing and approval. Compliance with these regulatory requirements can be time-consuming, expensive and resource-intensive, resulting in delays in product development and time-to-market. A strict regulatory environment restricts the market, especially for small and medium-sized biopharmaceutical companies with limited resources.

• Manufacturing Complexity and Scalability

Protein drugs often require complex manufacturing processes, including cell culture, protein expression, purification and formulation. Achieving consistent quality, scalability and cost-effectiveness in mass production can be challenging. Manufacturing challenges can limit the availability and affordability of protein therapy drugs, particularly in the treatment of rare or rare diseases. Overcoming manufacturing complexities and building strong manufacturing capabilities are critical for market growth and accessibility.

• Intellectual Property and Patent Expiration

Intellectual property rights and patent protection play a vital role in the protein medicine market. The industry faces patent expiration challenges as many pioneering protein therapies are nearing the end of their patent exclusivity. This opens the door for biosimilars and generic versions to enter the market, increasing competition and potential price erosion. Companies must focus on developing innovative protein-based therapies and generate new patents to maintain a competitive advantage.

This global protein therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Protein Therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In April 2020, Amgen announced the launch of biosimilar version of avastin (bevacizumab, which is used to treat certain type pf cancer
•  In March 2020, Biogen completed the acquisition of Nightstar Therapeutics, a clinical stage gene therapy company focused on adeno-associated virus (AAV) treatments for inherited retinal disorders

Global Protein Therapeutics Market Scope

The global protein therapeutics market is segmented on the basis of product, application, function, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Monoclonal Antibodies
• Insulin
• Fusion Protein
• Erythropoietin
• Interferon
• Human Growth Hormone
• Follicle Stimulating Hormone

Application

• Metabolic Disorders
• Immunologic Disorders
• Haematological Disorders
• Cancer
• Hormonal Disorders
• Genetic Disorders
• Others

Function

• Vaccines
• Enzymatic
• Regulatory
• Protein Diagnostics

End User

• Pharmaceutical Companies
• Healthcare Service Providers
• Research Organizations
• Academic Research Institutes

Global Protein Therapeutics Market Regional Analysis/Insights

The global protein therapeutics market is analysed and market size insights and trends are provided by country, product, application, function, and end user as referenced above.

The countries covered in the Protein Therapeutics market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of Middle East and Africa

North America dominates the global protein therapeutics market due to the adoption of advanced technology along with prevalence of favourable reimbursement policies and improved standard of living of the people.   

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the increasing demand for the advanced treatment options along with rising per capita income of the people.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The global protein therapeutics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global protein therapeutics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global protein therapeutics market. The data is available for historic period 2015-2020.

Competitive Landscape and Global Protein Therapeutics Market Share Analysis

The global protein therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global protein therapeutics market.

Some of the major players operating in the global protein therapeutics market are:

• Abbott. (U.S.)
• Amgen Inc. (U.S.)
• Baxter. (U.S.)
• Eli Lilly and Company. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Johnson & Johnson Services, Inc. (U.S.)
• Merck KGaA (Germany)
• Novo Nordisk A/S (Denmark)
• Pfizer Inc. (U.S.)
• Sanofi (France)
• AstraZeneca (U.K.)
• Boehringer Ingelheim International GmbH. (Germany)
• Teva Pharmaceutical Industries Ltd (Israel)
• Kyowa Kirin Co., Ltd. (Japan)
• AbbVie Inc. (U.S.)
• Generex Biotechnology Corp. (U.S.)
• CSL (Australia)
• Biogen Inc. (U.S.)
• Genentech, USA Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)

SKU-58748